08/10/03

2003059565

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/080976 A3

(51) International Patent Classification[7]: A61P 25/00, A61K 38/21, 47/18

(21) International Application Number: PCT/US01/51074

(22) International Filing Date: 26 October 2001 (26.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/282,614	9 April 2001 (09.04.2001)	US
60/330,404	18 October 2001 (18.10.2001)	US
10/035,397	25 October 2001 (25.10.2001)	US

(71) Applicant *(for all designated States except US)*: **CHIRON CORPORATION** [US/US]; 4560 Horton Street, Emeryville, CA 94608-2916 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **SHIRLEY, Bret, A.** [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **CHOE, Minna** [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **TELLERS, Melanie** [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **BABUKA, Susan** [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(74) Agents: **BLACKBURN, Robert, P.** et al.; Chiron Corporation, Intellectual Property, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE,

[Continued on next page]

(54) Title: HSA-FREE FORMULATIONS OF INTERFERON-BETA



(57) Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-β) and methods useful in their preparation are provided. The compositions comprise the IFN-β solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 5.0. methods for preparing these compositions, and for increasing solubility of IFN-β in pharmaceutical compositions, are provided.

162162

ACTION

WO 02/080976 A3

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA.

(84) **Designated States** *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) **Date of publication of the international search report:**
9 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.